Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 6

PMID 35664786

Authors

Helene Kaplon

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a 5-year relative survival rate of 5%. The desmoplastic stroma found in the tumor microenvironment of PDAC is suggested to be partly responsible for the resistance to most therapeutic strategies. This review outlines the clinical results obtained with an immune checkpoint inhibitor in PDAC and discusses the rationale to use a combination of chemotherapy and immune checkpoint therapy. Moreover, essential parameters to take into account in designing an efficient combination have been highlighted.

References

Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G . Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016; 14(1):282. PMC: 5041438. DOI: 10.1186/s12967-016-1037-z. View

Ma J, Sun D, Wang J, Han C, Qian Y, Chen G . Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunol Immunother. 2020; 69(3):365-372. PMC: 11027858. DOI: 10.1007/s00262-019-02452-3. View

Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F . Cancer-cell-secreted CXCL11 promoted CD8 T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019; 7(1):42. PMC: 6371476. DOI: 10.1186/s40425-019-0511-6. View

Kamath S, Kalyan A, Kircher S, Nimeiri H, Fought A, Benson 3rd A . Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2019; 25(5):e808-e815. PMC: 7216436. DOI: 10.1634/theoncologist.2019-0473. View

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View

Amin S, Baine M, Meza J, Lin C . The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database. Front Oncol. 2020; 10:1518. PMC: 7492650. DOI: 10.3389/fonc.2020.01518. View

Kodumudi K, Woan K, Gilvary D, Sahakian E, Wei S, Djeu J . A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16(18):4583-94. PMC: 3874864. DOI: 10.1158/1078-0432.CCR-10-0733. View

Blando J, Sharma A, Higa M, Zhao H, Vence L, Yadav S . Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019; 116(5):1692-1697. PMC: 6358697. DOI: 10.1073/pnas.1811067116. View

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

10.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

11.

Wahba J, Natoli M, Whilding L, Parente-Pereira A, Jung Y, Zona S . Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Cancer Immunol Immunother. 2018; 67(11):1753-1765. PMC: 6208825. DOI: 10.1007/s00262-018-2199-8. View

12.

Carstens J, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A . Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017; 8:15095. PMC: 5414182. DOI: 10.1038/ncomms15095. View

13.

Gunderson A, Rajamanickam V, Bui C, Bernard B, Pucilowska J, Ballesteros-Merino C . Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Oncoimmunology. 2021; 10(1):1900635. PMC: 7993148. DOI: 10.1080/2162402X.2021.1900635. View

14.

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

15.

Cao G, Wang J, Zheng X, Wei H, Tian Z, Sun R . Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. J Biol Chem. 2015; 290(50):29964-73. PMC: 4705966. DOI: 10.1074/jbc.M115.674010. View

16.

Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C . Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019; 14(1):141. PMC: 6688256. DOI: 10.1186/s13014-019-1345-6. View

17.

Emmenegger U, Man S, Shaked Y, Francia G, Wong J, Hicklin D . A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004; 64(11):3994-4000. DOI: 10.1158/0008-5472.CAN-04-0580. View

18.

Liang Y, Tsai J, Cheng Y, Chan K, Hsu W, Lee C . Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. Sci Rep. 2021; 11(1):9080. PMC: 8079421. DOI: 10.1038/s41598-021-88648-z. View

19.

Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M . Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer. Oncol Rep. 2019; 42(2):839-848. DOI: 10.3892/or.2019.7185. View

20.

Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791):549-555. PMC: 8762581. DOI: 10.1038/s41586-019-1922-8. View